MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology
Hematology-Oncology

Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma

MedXY Editorial TeamSep 22, 2026
maintenance therapysurvival outcomesmultiple myeloma

Highlight

1. Maintenance therapy after autologous hematopoietic cell transplantation (AHCT) significantly improves 3-year overall survival in newly diagnosed multiple myeloma (NDMM) patients compared to no maintenance.

2. Lenalidomide maintenance demonstrates the highest survival benefit (86% OS at 3 years), followed by bortezomib (83%) and thalidomide (80%).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Rapid Peak Cilta-Cel Expansion Predicts Delayed Neurotoxicity in Relapsed/Refractory Multiple Myeloma: Clinical and Translational Insights

Hematology-OncologyOct 29, 2026

Targeting Immunoglobulin Constant Domains: A Novel T-Cell Receptor-Based Immunotherapy for Multiple Myeloma

Hematology-OncologyOct 24, 2026

Mapping the Tumor Microenvironment in Multiple Myeloma: Insights from Single-Cell Analysis Across Disease Stages

Hematology-OncologyOct 16, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story